Additive composition for cell cryoprotectant
The use of heparin, dalteparin, or enoxaparin in cell cryopreservation agents addresses the inadequacies of existing methods by enhancing cell functions and stability post-thawing, while eliminating the risks of animal-derived components.
Patent Information
- Application Number
- PCT/KR2026/005899
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing cryopreservation methods using DMSO and other cryoprotectants fail to adequately prevent cell damage during freezing and thawing, posing risks of genetic mutations and contamination, especially for cell therapies like stem cells, and often rely on animal-derived components that can cause infections or immune responses.
An additive composition for cell cryopreservation agents containing heparin, dalteparin, or enoxaparin as anticoagulants, which are used at specific concentrations to minimize cell damage and enhance cell functions post-thawing, without relying on animal-derived serum.
The composition maintains or enhances cell viability, metabolic capacity, proliferative capacity, adhesion capacity, and secretory capacity of thawed cells, while avoiding the risks associated with animal-derived components.
Smart Images

Figure KR2026005899_12112026_PF_FP_ABST
Abstract
Description
Additive composition for cell cryopreservation agents
[0001] The present invention relates to an additive composition for a cell cryopreservation agent, a composition for cell cryopreservation comprising the same, and a method for cell cryopreservation using the same.
[0002] To utilize living cells derived from autologous, allogeneic, or xenogeneic sources as cell therapies, cells are isolated from tissues such as fat, bone marrow, umbilical cord blood, and peripheral blood, cultured and proliferated in vitro, and manipulated using physical, chemical, and biological methods. These cell therapies utilize living cells with short lifespans as raw materials. While these cells may be subcultured over extended periods to preserve them, doing so may alter cell characteristics due to genetic mutations and poses a risk of cell loss caused by contamination. Therefore, preservation methods are required to minimize cell loss resulting from such genetic mutations and contamination, and to maintain cell characteristics stably.
[0003] In particular, stem cells are undifferentiated cells found among the differentiated cells of tissues or organs. Because they possess self-renewal capabilities, allowing them to proliferate indefinitely while maintaining an undifferentiated state, and differentiation into specific tissues—capable of differentiating into any tissue cell within the body under certain conditions—stem cells are known to have very high medical utility and can be used to treat degenerative diseases or tissues damaged by trauma. To utilize these stem cells as cell therapies, it is essential to establish cell cryopreservation methods that guarantee cell viability and undifferentiation.
[0004] The cryopreservation method for cells involves preserving cells at extremely low temperatures of approximately -196°C by gradually lowering the temperature with liquid nitrogen. Cryoprotectants (hereinafter referred to as 'CPA'), such as glycerol, DMSO (dimethyl sulfoxide), keratin or gelatin hydrolysates, acetamide, propylene glycol, polyethylene glycol, animal or human-derived serum, or serum albumin, are used to prevent denaturation of cell membranes or cytoplasmic proteins caused by freezing or thawing. Through this gradual cooling and the use of CPA, the formation of ice crystals inside and outside the cell is inhibited, thereby preventing cell damage. However, the above-mentioned animal or human-derived serum or serum-derived components pose a risk of causing infection by viruses, prions, etc., and inducing an immune response, so they are not suitable for the preservation of cell therapy products intended for administration to the human body.
[0005] DMSO is currently the most widely used CPA, which not only effectively penetrates most cell types but also exhibits superior cell viability after thawing compared to other CPAs. However, despite these cryopreservation effects, existing CPAs containing DMSO are unable to sufficiently prevent cell damage caused by freezing and thawing.
[0006] Accordingly, there is a need to develop additives for cryopreservation agents that provide excellent cell cryopreservation effects while minimizing cell damage caused by freezing and thawing.
[0007] The objective of the present invention is to provide an additive composition for a cell cryopreservation agent capable of maintaining or enhancing cell function even after cryopreservation and thawing, and a composition for cell cryopreservation comprising the same.
[0008] Another objective of the present invention is to provide a cell cryopreservation method comprising the step of adding cells to the cell cryopreservation composition.
[0009] Another objective of the present invention is to provide a method for enhancing the function of thawed cells after cryopreservation, comprising the step of adding cells to the cell cryopreservation composition.
[0010] To achieve the above objective, the present invention provides an additive composition for a cell cryopreservation agent comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient.
[0011] According to one embodiment of the present invention, the cell may be a stem cell.
[0012] According to one embodiment of the present invention, the stem cells may be embryonic stem cells, mesenchymal stem cells, or induced pluripotent stem cells.
[0013] To achieve the other objectives mentioned above, the present invention provides a composition for cell cryopreservation comprising: an additive composition for a cell cryopreservation agent comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient; and a cell cryopreservation agent.
[0014] According to one embodiment of the present invention, the cell cryopreservation composition may not contain animal or human-derived serum.
[0015] According to one embodiment of the present invention, the dalteparin in the composition may be included at a concentration of 0.25 to 500 IU / mL, the enoxaparin at a concentration of 0.001 to 4 mg / mL, and the heparin at a concentration of 0.05 to 200 IU / mL.
[0016] According to one embodiment of the present invention, the dalteparin in the composition may be included at a concentration of 200 to 300 IU / mL, the enoxaparin at a concentration of 0.005 to 0.2 mg / mL, and the heparin at a concentration of 0.1 to 1.5 IU / mL.
[0017] According to one embodiment of the present invention, the cell comprises 1×10 per 40 µl of the cell cryopreservation composition.4 Up to 1×10 8 It can be added at a concentration of 1.
[0018] To achieve the aforementioned additional objective, the present invention provides a method for cryopreservation of cells comprising: a step of adding cells to a composition for cryopreservation of cells; and a step of cryopreserving the composition to which the cells have been added.
[0019] To achieve the aforementioned additional objective, the present invention provides a method for enhancing the function of thawed cells after cryopreservation, comprising the steps of: adding cells to the cell cryopreservation composition; cryopreserving the composition with added cells; and thawing the cryopreserved cells.
[0020] The composition of the present invention includes one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient, thereby improving the problem that existing cryopreservatives are unable to sufficiently prevent damage caused by freezing and thawing of cells. Compared to existing cryopreservatives, it can maintain or enhance one or more functions among viability, metabolic ability, proliferative ability, adhesion ability, and secretory ability of cells thawed after cryopreservation, and can have the effect of stably maintaining cell characteristics. In addition, the composition of the present invention can have an excellent cell cryopreservation effect without using animal-derived or human-derived serum or serum-derived components.
[0021] Figure 1 shows the results of measuring the viability, metabolic activity, and proliferation rate of cells thawed after cryopreservation in commercially available cell cryopreservation agents CPA 1 to CPA 5. Figure 1a shows cell viability (%), Figure 1b shows cell metabolic activity (%), and Figure 1c shows cell proliferation rate (%). In Figure 1, the 'CP' group is a culture preservation group that was not cryopreserved, and the '9F1D' group is a group that was frozen and thawed using a mixture of 10% DMSO and 90% FBS with CPA.
[0022] Figure 2 shows the results of measuring the viability, metabolic activity, and proliferation rate of cells thawed after cryopreservation by immersing them in a cell cryopreservation composition mixed with CBM (CPA 4) and various additives. Figure 2a shows the type of additive, Figure 2b shows the cell viability (%), Figure 2c shows the cell metabolic activity (%), and Figure 2d shows the cell proliferation rate (%). The control group is the 'CBM' group.
[0023] Figure 3 shows the results of evaluating the proliferation ability of cells thawed after cryopreservation by immersing CBM in a cell cryopreservation composition mixed with DAL, ENO, and HEP at various concentrations, respectively. Figure 3a shows the cell doubling time (hr), and Figure 3b shows the mRNA expression levels of cell proliferation markers (MCM2 and PCNA). The control group is the 'CBM' group.
[0024] Figure 4 shows the results of confirming cell death after cryopreservation and subsequent thawing by immersing CBM in a cell cryopreservation composition containing DAL, ENO, and HEP at various concentrations, respectively. Figure 4a shows the mRNA expression levels of intracellular apoptosis-related markers (p53, p21, BAX, Bcl2); Figure 4b shows the protein expression levels of phosphorylated-p53, p53, and p21 in cells immediately after thawing following cryopreservation, and in cells cultured for 4 hours after cryopreservation and thawing; Figure 4c shows the morphological characteristics of cells cultured for 4 hours after cryopreservation and thawing; and Figure 4d shows the results of flow cytometry analysis on cell death after cryopreservation and thawing. The control group is the 'CBM' group.
[0025] Figure 5 shows the results of evaluating the antioxidant capacity of cells thawed after cryopreservation by immersing them in a cell cryopreservation composition in which DAL, ENO, and HEP were mixed at various concentrations in CBM. Figure 5a shows the intracellular ROS levels, and Figure 5b shows the mRNA expression levels of antioxidant-related markers (SOD1, CAT, and GPx1). The control group is the 'CBM' group.
[0026] Figure 6 is a graph showing the adhesion rate to collagen type 1 of cells thawed after cryopreservation by immersing them in a cell cryopreservation composition in which DAL, ENO, and HEP were mixed at various concentrations, respectively, in CBM. The control group is the 'CBM' group.
[0027] Figure 7 shows the characteristics of cells thawed after cryopreservation by immersing them in a cell cryopreservation composition in which DAL, ENO, and HEP were mixed at various concentrations in CBM. Figure 7a is an image showing the number of colonies, Figure 7b shows the mRNA expression levels of intracellular stem cell markers (Oct4, Sox2, Nanog), and Figure 7c shows the results of confirming the expression of CD34, CD45, CD73, and CD90 markers. The control group is the 'CBM' group.
[0028] Figure 8 shows the results of evaluating the growth factor secretion ability of cells thawed after cryopreservation in a cell cryopreservation composition containing CP, CBM, and HEP. Figure 8a shows a representative membrane image of the human growth factor array performed on the culture supernatant on day 1 after thawing, and Figure 8b shows the results of quantifying the signal intensity of each band. Signal intensity was normalized with the CBM group set to 1, and all data were expressed as mean ± standard error (mean ± SEM). * indicates significance of p<0.05 compared to the CBM group, # indicates significance of p<0.05 compared to the CP group, and 'ND' means not detected.
[0029] The present invention will be described in detail below.
[0030] One aspect of the present invention relates to an additive composition for a cell cryopreservation agent comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient.
[0031] In this specification, the term “anticoagulant” refers to a substance that inhibits blood coagulation, and specifically may include heparin or an anticoagulant of the low molecular weight heparin class. In one embodiment, the anticoagulant may be one selected from the group consisting of heparin, dalteparin, and enoxaparin. The heparin may be conventional unfractionated heparin, and the dalteparin and enoxaparin may be anticoagulants of the low molecular weight heparin class. The heparin, dalteparin, and enoxaparin may be substances that exhibit anticoagulant activity by inhibiting the activity of coagulation factor Xa and / or factor IIa (Thrombin) through interaction with antithrombin III (ATIII). In the present invention, the heparin, dalteparin, and enoxaparin can be used for cryopreservation of cells, particularly for enhancing the function of cells thawed after cryopreservation.
[0032] Although heparin, dalteparin, and enoxaparin used in the present invention are all substances possessing anticoagulant activity, the present invention is not limited to their blood coagulation inhibitory action itself, but is characterized by using them to alleviate functional degradation caused during the freezing and thawing process of cells and to maintain or improve the functional quality of cells after thawing. That is, when the anticoagulants are added to a composition for cell cryopreservation, they can contribute to maintaining or enhancing at least one of the following functions after freezing and thawing: viability, metabolic capacity, proliferative capacity, adhesion capacity, antioxidant capacity, stem cell characteristics, or secretory capacity. Furthermore, since the functional indicators that are relatively better improved may differ depending on the type of anticoagulant, an appropriate anticoagulant can be selected and used according to the desired cell function.
[0033] In one embodiment, the heparin, dalteparin, and enoxaparin may each be used in the form of a biologically acceptable salt. The biologically acceptable salt refers to an organic or inorganic addition salt having a relatively non-toxic and harmless active effect on the subject to treatment, wherein side effects caused by the salt do not impede the beneficial efficacy of the substance. Such salts may include alkali metal salts (e.g., sodium salts, potassium salts, etc.) and alkaline earth metal salts (e.g., calcium salts, magnesium salts, etc.). For example, aluminum, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine, and zinc salts may be included.
[0034] The above anticoagulant may be included in a composition at an appropriate concentration for the purpose of cryopreservation of cells.
[0035] In one embodiment, when the anticoagulant is dalteparin, the dalteparin may be included at a concentration of 0.25 to 500 IU / mL, preferably 0.2 to 400 IU / mL, more preferably 2 to 400 IU / mL, more preferably 10 to 400 IU / mL, more preferably 100 to 400 IU / mL, more preferably 150 to 350 IU / mL, and more preferably 200 to 300 IU / mL. In one embodiment, the dalteparin may be used at 250 IU / mL.
[0036] In one embodiment, when the anticoagulant is enoxaparin, the enoxaparin may be included at a concentration of 0.001 to 4 mg / mL, preferably 0.001 to 1 mg / mL, more preferably 0.005 to 1 mg / mL, and even more preferably 0.005 to 0.2 mg / mL. In one embodiment, the enoxaparin may be used at 0.01 mg / mL.
[0037] In one embodiment, when the anticoagulant is heparin, the heparin may be included at a concentration of 0.05 to 200 IU / mL, preferably 0.1 to 50 IU / mL, more preferably 0.1 to 10 IU / mL, even more preferably 0.1 to 1.5 IU / mL, even more preferably 0.3 to 1 IU / mL, and even more preferably 0.4 to 0.6 IU / mL. In one embodiment, the heparin may be used at 0.5 IU / mL.
[0038] The concentration ranges of each of the above anticoagulants were not set arbitrarily, but were determined by synthesizing the results of candidate additive screening tests and cell function analysis after thawing. Specifically, within the tested concentration range, dalteparin improved the viability of thawed cells and some functional indicators, enoxaparin showed improvement effects in indicators related to metabolic capacity, proliferation capacity, and adhesion capacity, and heparin showed excellent effects in terms of proliferation capacity, antioxidant capacity, adhesion capacity, stem cell marker expression, and regulation of growth factor secretion capacity. In particular, in one embodiment, dalteparin showed excellent effects at 250 IU / mL, enoxaparin at 0.01 mg / mL, and heparin at 0.5 IU / mL, and based on this, the preferred concentration ranges of each of the above anticoagulants were derived. At concentrations lower than the above range, the effect of improving the function of cells thawed after cryopreservation may not be sufficient, and at concentrations excessive beyond the above range, adverse effects may occur on functional indicators such as cell metabolism or proliferation.
[0039] In one embodiment, the cell may be a stem cell.
[0040] In this specification, the term "stem cell" refers to an undifferentiated cell that has not yet differentiated, capable of infinite proliferation through self-renewal, and possessing pluripotency or multipotency, capable of differentiating into all types of cells when appropriate signals are provided as needed under the influence of the environment in which the cell is located.
[0041] The stem cells may be autologous or allogeneic stem cells and may be of any type of animal, including human and non-human mammals, and are not limited to whether the stem cells are derived from an adult or an embryo. Specifically, the stem cells may be embryonic stem cells, mesenchymal stem cells, or induced pluripotent stem cells, and more specifically, may be mesenchymal stem cells.
[0042] In this specification, the term "mesenchymal stem cell" refers to an undifferentiated stem cell isolated from human or mammalian tissue, which may be derived from various tissues. In particular, it may be umbilical cord-derived mesenchymal stem cells, cord blood-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, fat-derived mesenchymal stem cells, muscle-derived mesenchymal stem cells, nerve-derived mesenchymal stem cells, skin-derived mesenchymal stem cells, amniotic membrane-derived mesenchymal stem cells, and placenta-derived mesenchymal stem cells, and the technology for isolating stem cells from each tissue is already known in the industry.
[0043] In one embodiment, the cell cryopreservation agent may be any agent used for the cryopreservation of cells and is not particularly limited, and may be one prepared by a known method or commercially available. For example, the commercially available cell cryopreservation agent comprises dimethyl sulfoxide (DMSO) or propylene glycol and may further comprise, if necessary, sugars and / or starch, sodium salt, potassium salt, lactobionic acid, sodium carboxymethylcellulose, and / or phosphate buffer. For example, the DMSO or propylene glycol may be included in an amount of 5 to 15 weight%, the lactobionic acid may be included in an amount of 5 to 15 weight%, and the sodium carboxymethylcellulose may be included in an amount of 0.1 to 1 weight%. Non-limiting examples of the above sugars include sucrose and glucose, non-limiting examples of the above sodium salts include sodium hydroxide, sodium chloride, and sodium phosphate, and non-limiting examples of the above potassium salts include potassium hydroxide, potassium chloride, and potassium phosphate, but are not limited thereto.
[0044] In one embodiment, the composition may include a preservation solution, and the preservation solution may be a cell culture medium, a buffer solution, or an isotonic solution.
[0045] In one embodiment, the cryopreservation temperature may be -300 to -20 ℃, preferably -300 ℃ to -100 ℃, more preferably -250 ℃ to -150 ℃, and more preferably -220 ℃ to -170 ℃.
[0046] The above composition may inhibit damage caused by freezing and thawing of cells. During the freezing process for long-term preservation and the thawing process for reuse, cells suffer damage due to temperature changes. When freezing proceeds, extracellular water freezes first, resulting in an extracellular environment having a higher salt concentration than the intracellular environment. To maintain equilibrium, movement of intracellular water occurs, leading to plasmolysis. Cryoprotectants are used to prevent this, and these cryoprotectants are classified into two types: colligative cryoprotectants and cell-penetrating cryoprotectants. Colligative cryoprotectants inhibit the formation of ice crystals outside the cell, while cell-penetrating cryoprotectants penetrate the cell membrane to replace intracellular water and inhibit the formation of ice crystals during cryopreservation. Cell-penetrating cryopreserving agents, such as DMSO or glycerol, have been conventionally used for the cryopreservation of cells. However, in the case of cell-penetrating cryopreserving agents, they can be toxic to cells when their concentration is high. When the additive composition for cell cryopreservation of the present invention is used, the harmful effects of such cryopreserving agents can be suppressed, thereby increasing the viability of cells, and the function of cells thawed after cryopreservation can be enhanced.
[0047]
[0048] Another aspect of the present invention relates to a composition for cell cryopreservation comprising: an additive composition for cell cryopreservation comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient; and a cell cryopreservation agent. Alternatively, the present invention relates to a composition for enhancing the function of thawed cells after cryopreservation comprising: an additive composition for cell cryopreservation comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient; and a cell cryopreservation agent.
[0049] As the “anticoagulant,” “cell,” and “cryopreservative” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0050] In this specification, the term “enhancement of function of thawed cells after cryopreservation” does not mean only recovery to a state exactly identical to that of non-cryopreserved cells, but is used to mean that the functional indicators of thawed cells are relatively maintained or improved when compared to a group of cryopreservation agents alone or a control group not containing anticoagulants. The functional indicators may be one or more selected from cell viability, metabolic capacity, proliferative capacity, adhesion capacity, antioxidant capacity, inhibition of apoptosis, maintenance or increase in the expression of stem cell markers, and growth factor secretion capacity. Furthermore, it is not necessary for all functional indicators to be improved to the same level simultaneously, and a specific anticoagulant may exhibit a superior effect on a specific functional indicator.
[0051] In one embodiment, the composition for cell cryopreservation may not contain serum derived from animals or humans, or serum-derived components (such as albumin). The composition of the present invention, while not containing serum derived from animals or humans or serum-derived components, can prevent the formation of extracellular ice crystals, which is the role of serum proteins during cryopreservation, and can prevent cell contamination by serum proteins during cryopreservation. Furthermore, the composition of the present invention, while not containing serum or serum-derived components, can exhibit effects equivalent to or greater than those of using said serum or serum-derived components in terms of cell viability or functional enhancement after freezing and thawing.
[0052] The cell cryopreservation composition of the present invention is advantageous in that it can maintain or improve the functional quality of thawed cells without containing animal or human-derived serum or serum-derived components. In particular, the present invention has confirmed that functions such as viability, metabolic capacity, proliferative capacity, and adhesion capacity of cells after thawing can be improved without relying on serum components through a composition that combines a commercial cell cryopreservation agent with an anticoagulant. Furthermore, in an adhesion capacity evaluation performed under serum-free conditions, the anticoagulant-added group, particularly the enoxaparin and heparin-added group, showed improved cell adhesion capacity compared to the control group; thus, the composition of the present invention can be usefully applied as a serum-free cryopreservation platform.
[0053] Synthesizing the results of the following examples, the dalteparin, enoxaparin, and heparin of the present invention may all act to alleviate the functional decline of cells thawed after cryopreservation, but there may be differences in specific superior functional indicators. For example, dalteparin may be effective in improving viability and some antioxidant-related indicators, enoxaparin may be effective in improving metabolic capacity, proliferative capacity, and adhesion capacity, and heparin may exhibit relatively superior effects in proliferative capacity, antioxidant capacity, adhesion capacity, maintenance or increase of stem cell marker expression, and regulation of growth factor secretion capacity. Therefore, the anticoagulant according to the present invention is not selected based on a single indicator alone, but can be selectively applied according to the cell functions required after thawing.
[0054] The above anticoagulant may be included in the composition at an appropriate concentration to meet the purpose of enhancing the viability or function of frozen and thawed cells.
[0055] In one embodiment, when the anticoagulant is dalteparin, the dalteparin may be included at a concentration of 0.25 to 500 IU / mL, preferably 0.2 to 400 IU / mL, more preferably 2 to 400 IU / mL, more preferably 10 to 400 IU / mL, more preferably 100 to 400 IU / mL, more preferably 150 to 350 IU / mL, and more preferably 200 to 300 IU / mL. In one embodiment, the dalteparin may be used at 250 IU / mL. When the concentration of the above dalteparin is in the range of 100 to 400 IU / mL, specifically 150 to 350 IU / mL, and more specifically 200 to 300 IU / mL with respect to the total composition, not only is the effect of enhancing functions such as viability, metabolic ability, proliferation ability, and adhesion ability of cells thawed after freezing more excellent, but the effect of maintaining the characteristics of cells thawed after freezing is also excellent.
[0056] In one embodiment, when the anticoagulant is enoxaparin, the enoxaparin may be included at a concentration of 0.001 to 4 mg / mL, preferably 0.001 to 1 mg / mL, more preferably 0.005 to 1 mg / mL, and even more preferably 0.005 to 0.2 mg / mL. In one embodiment, the enoxaparin may be used at 0.01 mg / mL. When the concentration of the enoxaparin is in the range of 0.005 to 1 mg / mL, more specifically 0.005 to 0.2 mg / mL relative to the total composition, the effect of enhancing functions such as viability, metabolic ability, proliferative ability, and adhesion ability of cells thawed after freezing is superior, as well as the effect of maintaining the characteristics of cells thawed after freezing is superior.
[0057] In one embodiment, when the anticoagulant is heparin, the heparin may be included at a concentration of 0.05 - 200 IU / mL, preferably 0.1 - 50 IU / mL, more preferably 0.1 - 10 IU / mL, more preferably 0.1 - 1.5 IU / mL, more preferably 0.3 - 1 IU / mL, and more preferably 0.4 - 0.6 IU / mL. In one embodiment, the heparin may be used at 0.5 IU / mL. When the concentration of the heparin is in the range of 0.1 - 1.5 IU / mL, specifically 0.3 - 1 IU / mL, and more specifically 0.4 - 0.6 IU / mL relative to the total composition, the effect of enhancing functions such as viability, metabolic ability, proliferative ability, and adhesion ability of the cells thawed after freezing is superior, as well as the effect of maintaining the characteristics of the cells thawed after freezing is superior.
[0058] If the content of the anticoagulant in the above composition is below the lower limit, the effect of sufficient cryopreservation and the effect of enhancing functions such as viability, metabolic ability, proliferation ability, and adhesion ability of thawed cells become negligible, and if it exceeds the upper limit, there may be problems due to a decrease in cell metabolism, proliferation ability, and adhesion ability.
[0059] In one embodiment, the cell cryopreservation agent may be any agent used for the cryopreservation of cells and is not particularly limited, and may be one manufactured by a known method or commercially available.
[0060] In one embodiment, the cells are 1×10 per 40 µl of the cell cryopreservation composition. 4 Up to 1×10 9 Pieces, preferably 1×10 4 Up to 1×10 8 Dogs, more preferably 1×10 5 Up to 1×10 7 It can be added at a concentration of 1.
[0061] The cell cryopreservation composition of the present invention not only enhances the viability of cells thawed after cryopreservation but also has the effect of further enhancing various functions such as cell metabolic ability, proliferative ability, and adhesion ability compared to a control group using a composition that does not contain heparin.
[0062]
[0063] Another aspect of the present invention relates to a cell cryopreservation method comprising the steps of: adding cells to the cell cryopreservation composition; and cryopreserving the composition with added cells.
[0064] As the “anticoagulant,” “cell,” and “composition for cryopreservation” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0065] In one embodiment, the preservation may be carried out in a liquid nitrogen tank or a deep freezer. The liquid nitrogen tank may be maintained at about -300°C to about -100°C, about -250°C to about -150°C, or about -220°C to about -170°C, and the deep freezer may be maintained at about -100°C to about -50°C, or about -90°C to about -60°C.
[0066] In one embodiment, the preservation may last for 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 2 months, 3 months, 6 months, or 1 year or more.
[0067]
[0068] Another aspect of the present invention relates to a method for enhancing the function of thawed cells after cryopreservation, comprising the steps of: adding cells to the cell cryopreservation composition; and cryopreserving the composition with added cells.
[0069] As the “anticoagulant,” “cell,” and “composition for cryopreservation” of the present invention have already been described above, their description is omitted to avoid excessive duplication.
[0070] In one embodiment, the “cell function” may be one or more selected from cell viability, metabolic ability, proliferative ability and adhesion ability.
[0071] According to the above method, various functions such as viability, metabolic ability, proliferation ability, and adhesion ability of cells thawed after cryopreservation can be further enhanced compared to a control group using a composition that does not contain the above anticoagulant.
[0072]
[0073] The present invention will be described in detail below by way of examples, but the present invention is not limited by the following examples.
[0074]
[0075] <Example>
[0076] Experimental method
[0077] Isolation and Culture of Human Umbilical Cord-Derived Mesenchymal Stem Cells (UC MSCs)
[0078] Human umbilical cords (UC) were collected immediately after cesarean section delivery from healthy full-term pregnant women (n = 5, age 38.4 ± 2.6 years). The collected UC (n≥3) were washed twice with DPBS to remove blood residues. Subsequently, 1 g of UC fragments, cut into pieces of 2–4 mm using surgical scissors, were arranged at regular intervals in a 150 mm culture dish, and the dish was placed in a humidified incubator at 37°C with 5% CO2 for 1 hour to ensure the UC fragments adhered firmly to the bottom of the dish. A growth medium consisting of low-glucose DMEM (LG-DMEM; Welgene) supplemented with 10% FBS (fetal bovine serum; HyClone) and an antibiotic-antifungal solution (100 U / mL penicillin, 100 μg / mL streptomycin, and 0.25 μg / mL amphotericin B; Welgene) was carefully added to the dish. The culture medium was replaced with fresh medium every 2–3 days, and non-attached cells were removed. When the cells reached 80% density, they were incubated in trypsin-EDTA solution (0.05% trypsin, 0.53 mM EDTA; Welgene) for 3 minutes to detach them. Subsequently, the remaining tissue was filtered using a 100 μm cell filter (SPL Life Sciences, Pocheon, Korea), and cells were collected by centrifugation at 500 g for 5 minutes at 20 ℃, resulting in a sample size of 3,333 cells / cm². 2 Passage 1 (P1) was generated by redisplaying at a density. Subsequent experiments used cultured UC MSCs (CP) from passage 10 (P10) and thawed UC MSCs after cryopreservation. The above study was approved by the Institutional Review Board (IRB No. 06-2012-78) of Seoul National University Boramae Hospital.
[0079]
[0080] Cryopreservation and Thawing of UC MSC
[0081] Cells were added to a composition consisting of 10% dimethyl sulfoxide (DMSO; D8371; Invitrogen) and 90% FBS, which is the gold standard for cell cryopreservation, and then frozen.
[0082] A commercially available cell cryopreservation agent (CPA) for screening, namely, a composition comprising 10 wt% dimethyl sulfoxide (DMSO) and starch (CPA 1); a composition comprising 5 to 10 wt% DMSO, 5 to 10 wt% lactobionic acid (4-O-β-D-galactopyranosyl-D-gluconic acid), 1 to 5 wt% sucrose and sodium hydroxide or potassium hydroxide (CPA 2); a composition comprising 10 to 15 wt% DMSO, 5 to 10 wt% lactobionic acid, 1 to 5 wt% sucrose and sodium hydroxide or potassium hydroxide (CPA 3); and 10 wt% DMSO and sodium carboxymethylcellulose (sodium A composition (CPA 4, hereinafter referred to as “CBM (clinical basal medium)”) comprising 0.2 to 0.7 wt% of carboxymethylcellulose, 3 to 5 wt% of glucose, sodium chloride, potassium chloride, and phosphate buffer, and a composition (CPA 5) comprising 10 wt% of propylene glycol, 1 to 5 wt% of glucose, sodium chloride, and potassium chloride were used. The main compositions of CPA 1 to CPA 5 are as described in Table 1.
[0083] 1×10 cells 6 Dogs were placed in a freezing vial (Cryovial 430659; Corning, USA) with 40 µl of the above cryopreservative (CPA) and frozen. The freezing vial was then placed in a freezer container and kept in a -80°C refrigerator for 24 hours. After incubation overnight, the freezing vial was placed in liquid nitrogen and stored for one month.
[0084] Classification | Composition | Content (wt%) CPA1 | DMSO 10% | Starch- CPA2 | DMSO 5 | - 10% | Lactobionic Acid 5 | - 10% | Sucrose 1 | - 5% | Sodium Hydroxide 0.4 | - 0.5% | Potassium Hydroxide < 0.5% CPA3 | DMSO 10 | - 15% | Lactobionic Acid 5 | - 10% | Sucrose 1 | - 5% | Sodium Hydroxide 0.4 | - 0.5% | Potassium Hydroxide < 0.5% CPA4 | DMSO 10% | Sodium Carboxymethylcellulose 0.2 | - 0.7% | Glucose 3 | - 5% | Sodium Chloride-Potassium Chloride-Phosphoric Acid Buffer- CPA5 | Propylene Glycol 10% | Glucose 1 | - 5% | Sodium Chloride-Potassium Chloride-
[0085]
[0086] Cell metabolic and proliferative capacity testing
[0087] Immediately after thawing, cryopreserved cells were seeded into a 96-well plate at a concentration of 10,000 cells / well, and 100 μL of full growth medium was added. Cell metabolic capacity was measured at 0 hours after seeding, and cell proliferative capacity was measured at 24 hours. WST-1 solution (Daeil Lab Service, Seoul, Korea) was added to each well, and the cells were incubated for 2 hours in a humidified incubator at 37°C with 5% CO2. Optical densities (OD) were measured at 450 nm using an ELISA reader (Molecular Devices, San Jose, California, USA). A CBM group (a group with only the commercial cryopreservation agent CBM) was used as a control. The experiment was repeated three times.
[0088]
[0089] Analysis of cell viability and cell apoptosis
[0090] Cell viability and apoptosis were analyzed immediately after thawing the cryopreserved cells. Cell viability was confirmed by staining with trypan blue (Thermo Fisher Scientific). Cell apoptosis was 2×10⁻⁶ 5 Cells were washed with PBS, suspended in 100 µl of binding buffer, and stained by a dark reaction with 5 µl of Annexin V-FITC and 5 µl of PI (Propidium Oidide) for 15 minutes at room temperature. After the reaction, 100 µl of binding buffer was added, and cell apoptosis was measured within 1 hour using a flow cytometer (FACS Canto II, BD Biosciences, San Jose, USA).
[0091]
[0092] Cell adhesion analysis
[0093] Immediately after thawing, cryopreserved cells were seeded into 96-well plates at a concentration of 32,000 cells / well. 100 µl of full growth medium was added, and the plates were incubated for 10 minutes in a humidified incubator at 37°C with 5% CO2. After incubation, the plates were washed with PBS to remove unattached cells, and the attached cells were treated with WST-1 solution. Optical density (OD) was measured at 450 nm using an ELISA reader. A CBM group (a group treated only with the commercial cryopreservative CBM) was used as a control. The experiment was repeated three times.
[0094]
[0095] Intracellular ROS measurement
[0096] To detect intracellular ROS, the DCFDA / H2DCFDA cell ROS assay kit (ab113851; Abcam, UK) was used. Briefly, thawed cryopreserved cells were placed in equal numbers into tubes and incubated at room temperature for 0, 0.5, and 1 hour, respectively. Subsequently, the cells were stained with 10 μM DCFDA at 37 °C for 30 minutes and then washed with phenol red-free medium. The cells were then seeded into 96-well black-bottom plates (30296; SPL, Korea), and fluorescence intensity was detected at excitation / emission wavelengths of 488 nm / 535 nm using a Victor X3 Multi-Mode Microplate Reader (PerkinElmer, USA). The fluorescence intensity of each experimental group was expressed as a normalized relative value with respect to the CBM group.
[0097]
[0098] Cell proliferation analysis
[0099] Cell proliferation was analyzed by calculating the cumulative population doubling level (CPDL) and population doubling time (PDT). Cells were separated when they reached 80% density, counted at each passage using the trypan blue exclusion method, and then re-plated. CPDL was calculated by summing the population doubling (PD) values of each passage and the previous passage. PD and PDT were calculated using the following formulas: PD = Log (Nf / Ni) / Log2, PDT = CT / PD, where CT represents the total culture time (h), and Nf and Ni represent the final number of harvested cells and the initial number of inoculated cells, respectively (Jo et al., 2008).
[0100]
[0101] RNA extraction and reverse transcription quantification polymerase chain reaction (RT-qPCR)
[0102] Total RNA from cells was extracted using the eCube RNA Mini kit (PhileKorea Technology, Seoul, Korea) according to the manufacturer's instructions, and its concentration and purity were determined using the NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). 1 µg of the isolated total RNA and cDNA were synthesized using the SuperioScript III cDNA Synthesis Kit (Enzynomics, Daejeon, Korea) according to the manufacturer's instructions. Subsequently, RT-qPCR was performed using the LightCycler®480 (Roche Applied Science, Mannhein, Germany), the SYBR Prime Script™ RT-qPCR kit (Takara Biotechnology, Dalian, China), and the TaqMan® Gene Expression Assay kit (Applied Biosystems, Austin, TX, USA) according to the manufacturer's instructions. The mRNA expression levels of each gene were normalized using the GAPDH housekeeping gene, and then 2- ΔΔCq Relative expression levels were analyzed using the method (qPCR relative quantification analysis) (Livak & Schmittgen, 2001). The experiment was repeated twice. The primers and probes used in the RT-qPCR above are shown in Table 2 below.
[0103] No. | Classification | Nucleotide Sequence (5'-3') Sequence No. 1 | Minichromosome Maintenance Complex Component 2 (MCM2) | FCGTACTGATGCCCTCACCTC | Sequence No. 1 | RATCATCCAGAGCCAGTCCCT | Sequence No. 2 | Proliferating cell nuclear antigen (PCNA) | FGGCGTGAACCTCACCAGTAT | Sequence No. 3 | RTCTCCTGGTTTGGTGCTTC | Sequence No. 43 | p53 | FAGTCACAGCACATGACGGAG | Sequence No. 5 | RACAAACGCACCTCAAAGC | Sequence No. 64 | p21 | FACCACTGGAGGGTGACTTC | Sequence No. 7 | RACAAACGCACCTCAAAGC | Sequence No. 85 | Bcl-2 antagonist X (Bax) | FTTTCTGACGGCAACTTCAACT | Sequence No. 9 | RGGAGGAAGTCCAATGTCCAG | Sequence No. 106 | B-cell lymphoma 2 (Bcl-2)FGATGGGATCGTTGCCTTATGC Sequence No. 11RCAGTCTACTTCCTCTGTGATGTT Sequence No. 127 Superoxide dismutase type 1 (SOD1)FCTGAAGGCCTGCATGGATTC Sequence No. 13RCCAAGTCTCCAACATGCCTCTC Sequence No. 148 Catalase (CAT)FAGGGGCCTTTGGCTACTTTG Sequence No. 15RACCCGATTCTCCAGCAACAG Sequence No. 169 Gluathione peroxide 1 (GPx1)FCCGGGACTACACCCAGATGA Sequence No. 17RCGTTCTCCTGATGCCCAAAC Sequence No. 1810 SRY-box transcription factor 2 (Sox2)FCGTGAAGCTGGAGAAGGAGAAGCTG Sequence No. 19RCAAGGGCCGCAGCTTACACATGTTC Sequence No. 2011 SRY-box transcription factor 2 (Sox2)FGCTACAGCATGATGCAGGACCA Sequence No. 21RTCTGCGAGCTGGTCATGGAGTT Sequence No. 2212Nanog homeobox(NANOG)FCATGAGTGTGGATCCAGCTTG Sequence No. 23RCCTGAATAAGCAGATCCATGG Sequence No. 2413Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)FGTCTCCTCTGACTTCAACAGCG Sequence No. 25RACCACCCTGTTGCTGTAGCCAA Sequence No. 26
[0104]
[0105] Western Blotting
[0106] After washing UC MSCs with PBS, they were placed in lysis buffer containing RIPA buffer (Thermo Fisher Scientific) and a 100X protease / phosphatase inhibitor cocktail (Cell Signaling Technology, Danvers, MA, USA) and incubated on ice for 30 minutes. The resulting cell lysate was centrifuged at 13,200 xg at 4°C for 20 minutes to obtain cell protein extracts. The concentration of the extracted proteins was determined by the BCA method (Thermo Fisher Scientific), mixed with SDS sample buffer (Bio-Rad, Hercules, CA, USA), and heated at 98°C for 10 minutes. Subsequently, the proteins were separated onto an SDS-PAGE gel, transferred to a PVDF membrane (Millipore, Burlington, MA, USA), and blocked with 5% skim milk or 5% bovine serum albumin (Sigma Aldrich, Saint Louis, MO, USA). The above membrane was incubated overnight at 4°C with the primary antibody, and then further incubated for 60 minutes at room temperature with the HRP-conjugated secondary antibody. Protein signals were detected using the EZ-Western Lumi Femto (Daeil Lab Service) with the ChemiDoc MP Imaging System (Bio-Rad). The CBM group was used as a control. The antibodies used in this study are shown in Table 3 below.
[0107] No. | Classification | Antibody | 11th Antibody | Phospho-p53 | 21st Antibody | p53 | 31st Antibody | p21 | 41st Antibody | GAPDH | 52nd Antibody | Anti-rabbit IgG | 62nd Antibody | Anti-mouse IgG
[0108]
[0109] CFU-F analysis
[0110] CFU-F analysis was performed using the previously described method (2008, Chris). Briefly, 1 × 10⁶ cells were placed in a 150 mm dish. 2 cells / cm 2 Cells were seeded at a density of [value] and cultured for 14 days. On the 14th day of culture, cells were washed twice with DPBS, fixed with 4% paraformaldehyde for 20 minutes, stained with 0.1% crystal violet (Sigma Aldrich) for 1 hour, and washed with tap water. A group of more than 50 cells with a fibroblast phenotype was defined as a CFU-F colony.
[0111]
[0112] Flow cytometry analysis
[0113] A total of 9 antibodies were used for flow cytometry analysis: CD90-FITC, CD34-PE, CD45-PE, CD73-PE (BD Biosciences, San Jose, CA, USA). 5×10 5The cells were washed with ice-cold DPBS supplemented with 2% FBS. The cells were incubated with cell surface antibodies in a dark room at 4°C for 30 minutes, washed once with ice-cold DPBS, centrifuged at 500g for 3 minutes, and then fixed with 1% paraformaldehyde solution. Data were obtained by analyzing 10,000 events on an FC500 flow cytometer (Beckman Coulter, Brea, CA, USA) equipped with CXP Cytometer 2.3 software (Beckman Coulter). All analyses were standardized using allo-specific IgG as a negative control.
[0114]
[0115] Human Growth Factor Array Analysis
[0116] After thawing the cryopreserved cells, they were cultured for one day, and the culture supernatant was collected. The collected supernatant was centrifuged to remove cell debris and stored at -80°C until analysis. To analyze the growth factors secreted by the cells, the Human Growth Factor Array C1 (RayBiotech, Norcross, GA, USA), capable of detecting 41 types of proteins, was performed according to the manufacturer's instructions. Signals on the membrane were visualized using a LAS-4000 device (GE Healthcare), and the intensity of each spot was calculated using ImageJ with the Protein Array Analyzer macro applied. For inter-group comparison, the intensity of each spot was normalized to the positive control signal, and protein expression levels were semi-quantitatively analyzed using the RayBiotech analysis tool software provided by the supplier.
[0117]
[0118] Statistical analysis
[0119] The experiment was repeated three times, and all data were expressed as mean ± standard error (SE). The significance of differences was determined using independent t-tests with Tukey's test and one-way analysis of variance (ANOVA). All statistical analyses were performed using SPSS software version 20 (SPSS Inc, Chicago, IL, USA). A p-value less than 0.05 (p < 0.05) was considered statistically significant.
[0120]
[0121] Experimental results
[0122] Test Example 1: Screening and Selection of Clinical Grade Cryopreservatives (CPA)
[0123] UC MSCs were placed in commercially available cell cryopreservation agents (CPA), CPA 1 to CPA 5, respectively, and then frozen and thawed. The viability, metabolic capacity, and proliferative capacity of the cells were evaluated to screen for the CPA that most enhanced cell function (see Table 1). The control group consisted of a culture preserved group (CP) and a group that was frozen and thawed using a mixture of 10% DMSO and 90% FBS as the CPA (9F1D).
[0124] Specifically, 1×10 with 40 µl of each of the above CPA 6 Canine cells were placed in a freezing vial and immersed in liquid nitrogen (LN2) at -196 °C for at least 30 days, and then thawed and evaluated cell viability, metabolic activity, and proliferation rate (Fig. 1).
[0125] As shown in Figure 1a, although the survival rate of all CPA groups decreased compared to the control CP group due to freeze-thaw, the cell survival rate of the 9F1D group was 87.5%, and the cell survival rates of the CPA1 and CPA4 groups were 91.1% and 90.7%, respectively, indicating significantly high survival rates.
[0126] In addition, as shown in Figure 1b, in the WST-1 assay used to evaluate cell metabolic activity after freeze-thaw, the cell metabolic activity of the 9F1D group was significantly reduced to 0.44 times compared to the CP group. Meanwhile, the metabolic activity of the CPA1 and CPA4 groups increased significantly to 1.9 times and 1.5 times, respectively, compared to the 9F1D group, which was consistent with the results of the cell viability evaluation.
[0127] In addition, as shown in Figure 1c, WST-1 assays were performed to evaluate the proliferation capacity of each cell after immersing and freezing / thawing cells in each CPA for 24 hours. As a result, the cell proliferation rate of all CPA groups decreased compared to the CP group due to freezing and thawing. However, the cell proliferation rates of the CPA1 and CPA4 groups increased significantly by 1.4 times and 1.5 times, respectively, compared to the 9F1D group.
[0128] Looking at the results above, the cell viability and proliferation rates of the CPA1 group were superior to those of the CPA 4 group, but considering the GMP grade, 'CPA 4' was selected as the basic CPA for subsequent experiments.
[0129]
[0130] Test Example 2: Screening of Additives for Cell Cryopreservatives
[0131] A composition for cell cryopreservation of Table 5 below was prepared by adding one, two, or three selected from the candidate additives (a total of 8 types) of Table 4 and Figure 2a below to CBM (clinical basal medium, CPA 4) at various concentrations.
[0132] No. Additive Full Name Type 1 HSA Human Serum Albumin Protein-based substances 2 HPL Human platelet lysate 3 DEX Dextran Polysaccharide-based substances 4 HE SH Hydroxyethyl starch 5 H A Sodium hyaluronate 6 DAL D Alteparin sodium Anticoagulants 7 ENE Noxaparin sodium 8 HEP Heparin sodium
[0133] 구분CBM첨가제9F1D-10% DMSO, 90% FBSCBM+-1 조합HSA+HSA 8%HPL+HPL 20%DEX+DEX 1.25%DEX+DEX 5%HES+HES 5%HA+HA 0.25% DEX+HSA, HA+HA+HA 6%, DEX 1%HSA, HA+HSA 7%, HA 0.05%HPL, DEX+HPL 20%, DEX 1.25%HPL, DEX+HPL 20%, DEX 5%HPL, HES+HPL 20%, HES 5%HPL, HA+HPL 20%, HA+HPL, HADEX 50%. 1.25%, HA 0.05%DEX, HA+DEX 5%, HA 0.05%HES, HA+HES 3.5%, HA 0.05%DEX, HES+DEX 1.25%, HES 5%HSA, HPL+HSA 8%, HPL 20%3, HPL+HSA, HPL+HSA, DEX 8% HPL 20%, DEX 1.25%HSA, HPL, HA+HSA 8%, HPL 20%, HA 0.05%HSA, DEX, HA+HSA 5%, DEX 1%, HA 0.05%HPL, DEX, HES+HPL 20%, DEX 1.25%, HES+HPL, DEX 1.25%, HPL, HA+HSA, DEX+ 20%, DEX 1.25%, HA 0.05%HPL, DEX, HA+HPL 20%, DEX 5%, HA 0.05%HPL, HES, HA+HPL 20%, HES 5%, HA 0.05%DEX, HES, HA+DEX 1.25%, HA+HPL 105%. 조합DAL+DAL 0.25 IU / mlDAL+DAL 2.5 IU / mlDAL+DAL 25 IU / mlDAL+DAL 250 IU / mlDAL+DAL 1,000 IU / mlDAL+DAL 10,000 IU / ml 0.01 mg / mlENO+ENO 0.1 mg / mlENO+ENO 0.4 mg / mlENO+ENO 40 mg / mlHEP+HEP 0.05 IU / mlHEP+HEP 0.5 IU / mlHEP+HEP 5 IU / mlHEP+HEP+2000mlHEP, IU / ml
[0134] Subsequently, 1×10 with 40 µl of each of the above compositions 6 10 UC MSCs were placed in a freezing vial and immersed in liquid nitrogen (LN2) at -196 °C for at least 30 days, and then thawed and evaluated cell viability, metabolic activity, and proliferation rate (Fig. 2).
[0135] Looking at Figure 2b, it can be seen that the cell viability of the groups combining one candidate additive—the HSA 8% group, DEX 1.25% group, HA 0.05% group, and HEP 0.5 IU / ml group—significantly increased by 1.03, 1.02, 1.02, and 1.03 times, respectively, compared to the CBM group. Meanwhile, in the case of groups combining two or three candidate additives, not only did the cell viability not increase, but it actually showed a tendency to decrease significantly.
[0136] In addition, looking at Figure 2c, it can be seen that the cellular metabolic activity of the groups combining one candidate additive—HSA 8% group, HSA 10% group, HPL 20% group, DEX 1.25% group, and HA 0.05% group—significantly increased by 1.10 times, 1.04 times, 1.02 times, 1.04 times, and 1.10 times, respectively, compared to the CBM group. In addition, in the case of groups combining two or three candidate additives, cellular metabolic activity was significantly increased compared to the CBM group. Specifically, the cellular metabolic activity of the HSA 6% + DEX 1%, HSA 7% + HA 0.05%, DEX 1.25% + HA 0.05%, and HES 3.5% + HA 0.05% groups increased by 1.11, 1.12, 1.11, and 1.06 times, respectively, compared to the CBM group, and the cellular metabolic activity of the HPL 10% + DEX 1.25% + HA 0.05% group increased by 1.05 times compared to the CBM group. Furthermore, among the groups combining one candidate additive, the cellular metabolic activity of the group with DAL added at concentrations of 0.25–250 IU / ml increased compared to the CBM group, and in particular, the cellular metabolic activity of the 25 IU / ml concentration group increased to a maximum of 1.15 times compared to the CBM group. In addition, among the groups combined with one candidate additive, the cellular metabolic activity of the group with ENO added at a concentration of 0.001–0.1 mg / ml increased compared to the CBM group, and in particular, the cellular metabolic activity of the 0.01 mg / ml concentration group increased to a maximum of 1.24 times compared to the CBM group. In addition, among the groups combined with one candidate additive, the cellular metabolic activity of the group with HEP added at a concentration of 0.05–50 IU / ml increased compared to the CBM group, and in particular, the cellular metabolic activity of the 0.5 IU / ml concentration group increased to a maximum of 1.33 times compared to the CBM group.
[0137] In addition, looking at Figure 2d, the proliferation ability of each cell was evaluated by performing a WST-1 assay after immersing and freezing / thawing cells in each composition for 24 hours. As a result, it can be seen that the cell proliferation rates of the HSA 8% group, HPL 20% group, DEX 1.25% group, HES 5% group, and HA 0.05% group were significantly increased by 1.16 times, 1.06 times, 1.05 times, 1.06 times, and 1.11 times, respectively, compared to the CBM group. In addition, the cell proliferation rates of the two combination groups (HSA 6% + DEX 1%, HSA 7% + HA 0.05%, DEX 1.25% + HA 0.05%, and HES 3.5% + HA 0.05%) increased by 1.15, 1.12, 1.04, and 1.08 times, respectively, compared to the CBM group, and the cell proliferation rate of the three combination group (HPL 10% + DEX 1.25% + HA 0.05%) increased by 1.06 times compared to the CBM group. Furthermore, among the groups combining one candidate additive, the cell proliferation rate of the group with DAL added at concentrations of 2.5–250 IU / ml increased compared to the CBM group, and in particular, the cell proliferation rate of the 2.5 IU / ml concentration group increased to a maximum of 1.16 times compared to the CBM group. In addition, the cell proliferation rate of the group with ENO added at concentrations of 0.001–4 mg / ml increased compared to the CBM group, and in particular, the cell proliferation rate of the 0.01 mg / ml concentration group increased to a maximum of 1.39 times compared to the CBM group. In addition, the cell proliferation rate of the group with HEP added at concentrations of 0.5–200 IU / ml increased compared to the CBM group, and in particular, the cell proliferation rate of the 0.5 IU / ml concentration group increased to a maximum of 1.48 times compared to the CBM group.
[0138] From the above results, it can be seen that among the above candidate additives, DAL, HSA, and HEP increase the viability of cells thawed after cryopreservation, and that HEP and ENO improve the metabolic and proliferative capacity of cells thawed after cryopreservation.
[0139]
[0140] Test Example 3: Effect of enhancing the proliferation ability of thawed cells after cryopreservation
[0141] Compositions for cell cryopreservation were prepared by mixing DAL, ENO, and HEP, respectively, into CBM (CPA 4) at various concentrations. Subsequently, 40 µl of each of the above compositions was combined with 1×10 6 10 UC MSCs were placed in a freezing vial and immersed in liquid nitrogen (LN2) at -196 °C for at least 30 days. After thawing the cells, the same number of cells were inoculated and cultured every 4 days, and the population doubling time (PDT, Population Doubling time, hr) immediately after thawing and after subculture was measured using the trypan blue assay (Fig. 3).
[0142] Looking at Figure 3a, it can be seen that the cell doubling time of the CBM group was 38.4 hours, which is a significant increase of 8.6 hours compared to the control group CP (29.8 hours). On the other hand, the HEP 0.5 IU / ml group showed the highest cell proliferation ability, with a cell doubling time of 32.9 hours, which is a significant decrease of 5.5 hours compared to the CBM group. Meanwhile, after repeated subculture, the cell proliferation ability of all test groups was found to recover to a level similar to that of the control group CP.
[0143] Meanwhile, MCM2 (Minichromosome maintenance protein 2), Ki-67, and PCNA (proliferating cell nuclear antigone) are proteins that serve as markers of cell proliferation. The relative expression levels of cell proliferation-related markers were confirmed by performing qPCR on cells frozen and thawed in each cryopreservation composition (Fig. 3b).
[0144] Looking at Figure 3b, it can be seen that the MCM2 and PCNA mRNA expression in the CBM group decreased by 0.62 and 0.81 times, respectively, compared to the control CP group. On the other hand, PCNA mRNA expression in the DAL 250 IU / ml, ENO 0.01 mg / ml, and HEP 0.5 IU / ml groups was found to have significantly increased by 1.24, 1.13, and 1.24 times, respectively, compared to the CBM group. Additionally, MCM2 mRNA expression in the ENO 0.01 mg / ml and HEP 0.5 IU / ml groups was found to have significantly increased by 1.27 and 1.42 times, respectively, compared to the CBM group.
[0145] From the above results, it can be seen that the cell proliferation ability of the HEP group, especially the HEP 0.5 IU / ml group, is the best.
[0146]
[0147] Test Example 4: Effect of reducing apoptosis in thawed cells after cryopreservation
[0148] 4-1: Expression levels of apoptosis-related markers in cells immediately after thawing
[0149] To evaluate the apoptosis of cells thawed after cryopreservation in each cryopreservation composition, the expression levels of intracellular apoptosis-related markers (p53, p21, BAX, Bcl2) were checked immediately after thawing the cryopreserved cells (Fig. 4a).
[0150] Looking at Figure 4a, it can be seen that the gene expression levels of 53 and p21 in the CBM group increased significantly by 1.55 times and 1.65 times, respectively, compared to the CP group. On the other hand, the gene expression levels of p53 in the DAL 250 IU / ml group and the HEP 0.5 IU / ml group decreased significantly by 0.71 times and 0.84 times, respectively, compared to the CBM group.
[0151] In addition, the BAX gene expression level of the CBM group was not significantly different from that of the CP group, whereas the BAX gene expression level of the ENO 0.01 mg / ml group decreased by 0.92 times compared to the CBM group.
[0152] In addition, the Bcl-2 gene expression level in the CBM group was significantly reduced by 0.59 times compared to the CP group, whereas the Bcl-2 gene expression levels in the DAL 25 IU / ml and 250 IU / ml groups were significantly increased by 1.29 times and 1.28 times, respectively, compared to the CBM group, and the Bcl-2 gene expression levels in the ENO 0.001 mg / ml and 0.1 mg / ml groups were significantly increased by 1.28 times, respectively, compared to the CBM group.
[0153] 4-2: Expression levels of apoptosis-related proteins in cells cultured immediately after thawing and for 4 hours after thawing
[0154] In addition, the protein expression levels of phosphorylated-p53, p53, and p21 in cells immediately after thawing following cryopreservation, and in cells cultured for 4 hours after cryopreservation and thawing, were confirmed by Western blot (Fig. 4b).
[0155] Looking at Figure 4b, it can be seen that the protein expression level of phosphorylated-p53 in the CBM group immediately after thawing increased compared to the CP group. Additionally, the protein expression levels of phosphorylated-p53, p53, and p21 in the CBM group after 4 hours of thawing were found to have increased compared to immediately after thawing. On the other hand, the protein expression level of phosphorylated-p53 in the HEP 0.5 IU / ml group decreased compared to the CBM group immediately after thawing and after 4 hours of thawing. Furthermore, while the protein expression levels of p53 and p21 in the HEP 0.5 IU / ml group were no different from those of the CBM group immediately after thawing, the protein expression levels of p53 and p21 were found to be lower compared to the CBM group after 4 hours of thawing.
[0156] 4-3: Cell Morphology Analysis
[0157] In addition, the morphological characteristics of cells cultured for 4 hours after cryopreservation and thawing were confirmed (Fig. 4c).
[0158] Looking at Figure 4c, it can be seen that the CBM group cultured for 4 hours after thawing had significantly fewer cells attached to the culture dish compared to the CP group, whereas the HEP 0.5 IU / ml group had a level of attached cells similar to that of the CP group.
[0159] 4-4: Cell Death Analysis
[0160] Flow cytometry analysis was performed on the apoptosis of cells thawed after cryopreservation (Fig. 4d).
[0161] Looking at Figure 4d, it can be seen that early apoptosis (Annexin V FITC+ / PI- staining) and late apoptosis (Annexin V FITC+ / PI+ staining) in the HEP 0.5 IU / ml group were significantly reduced by 0.55 times and 0.60 times, respectively, compared to the CBM group.
[0162] From the above results, it can be seen that the cell viability of the HEP group is the best.
[0163]
[0164] Test Example 5: Effect of reducing ROS production in thawed cells after cryopreservation
[0165] 5-1: Reduction of intracellular ROS levels
[0166] Cells thawed after cryopreservation in each cryopreservation composition were stained with DCFDA at room temperature for 0 hours, 0.5 hours, and 1 hour, respectively, to measure intracellular ROS levels (Fig. 5a).
[0167] Looking at Figure 5a, the intracellular ROS levels in the CBM group increased significantly compared to the CP group, reaching 1.4 times at 0 hours, 1.6 times at 0.5 hours, and 1.3 times at 1 hour. On the other hand, the intracellular ROS levels in the HEP 0.5 IU / ml group decreased significantly compared to the CBM group, reaching 0.83 times at 0 hours, 0.74 times at 0.5 hours, and 0.82 times at 1 hour. Additionally, the intracellular ROS levels in the ENO 0.01 mg / ml group decreased significantly compared to the CBM group, reaching 0.83 times at 0.5 hours.
[0168] 5-2: Increased Expression of Antioxidant-Related Markers
[0169] qRT-PCR was performed on cells immediately after thawing following cryopreservation in each cryopreservation composition to analyze the expression of antioxidant-related genes (Fig. 5b).
[0170] Looking at Figure 5b, it can be seen that CAT mRNA expression in the CBM group was significantly reduced by 0.59 times compared to the CP group. Meanwhile, SOD1 mRNA expression in the DAL 250 IU / ml group and the HEP 0.5 IU / ml group was significantly increased by 1.2 times compared to CBM, respectively. In addition, GPx1 mRNA expression in the HEP 0.5 IU / ml group was significantly increased by 1.2 times compared to CBM.
[0171] From the above results, it can be seen that the HEP group has the best antioxidant capacity.
[0172]
[0173] Test Example 6: Effect of increasing adhesion ability of thawed cells after cryopreservation
[0174] Cells thawed after cryopreservation in each cryopreservation composition were attached to a collagen type 1 plate in a serum-free medium for 10 minutes. Non-attached cells were washed away, and only attached cells were subjected to WST analysis to determine the cell attachment rate (Fig. 6).
[0175] Looking at Figure 6, the cell adhesion rate to collagen type 1 decreased in all groups thawed after cryopreservation compared to the CP group, and in particular, the cell adhesion rate of the CBM group decreased significantly by 0.61 times compared to the CP group. On the other hand, the cell adhesion rate of the DAL 25 IU / ml group increased by 1.09 times compared to the CBM group. The cell adhesion rate of the ENO 0.001-0.1 mg / ml groups increased compared to the CBM group, and in particular, the cell adhesion rate of the ENO 0.01 mg / ml group increased by up to 1.52 times compared to the CBM group. In addition, the cell adhesion rate of the HEP 0.05-50 IU / ml groups increased compared to the CBM group, and in particular, the cell adhesion rate of the 0.5 IU / ml group increased significantly by up to 1.62 times compared to the CBM group.
[0176] From the above results, it can be seen that the HEP group, especially the HEP 0.5 IU / ml group, has the best adhesion ability.
[0177]
[0178] Test Example 7: Characteristics of cells thawed after cryopreservation
[0179] The colony-forming ability of cells thawed after cryopreservation in each cryopreservation composition was evaluated by crystal violet staining (Fig. 7a).
[0180] Looking at Figure 7a, the number of colonies in the CBM group decreased significantly to 0.60 times compared to the CP group, and it can be confirmed that the number of colonies in the DAL, ENO, and HEP groups also showed no significant difference from the CBM group. In other words, although the number of colonies decreased due to freezing and thawing, no difference was observed depending on the type of CPA used.
[0181] In addition, the expression of stem cell markers Oct4, Sox2, and Nanog in cells thawed after cryopreservation in each cryopreservation composition was confirmed by qRT-PCR (Fig. 7b).
[0182] Looking at Figure 7b, the expression of stem cell markers in the CBM group decreased compared to the CP group, whereas the expression of stem cell markers Oct4, Sox2, and Nanog in the HEP group significantly increased compared to the CBM group, and in the DAL group, only the expression of Sox2 showed a significant increase compared to the CBM group. In other words, although the expression of stem cell markers decreased due to freezing and thawing, an increase in the expression of stem cell markers was observed in the HEP group.
[0183] In addition, CD34, CD45, CD73, and CD90 markers were stained on cells thawed after cryopreservation in each cryopreservation composition, and expression was confirmed using a flow cytometer (Fig. 7c).
[0184] Looking at Figure 7c, it can be seen that cryopreservation and thawing of cells do not affect the expression of CD markers, and there is no difference in CD marker expression depending on the type of CPA.
[0185]
[0186] Test Example 8: Effect of adding heparin on improving growth factor secretion ability of thawed cells after cryopreservation
[0187] 8-1: Human Growth Factor Array Analysis
[0188] After thawing the cryopreserved cells, they were cultured for one day, and the culture supernatant was collected. The collected supernatant was centrifuged to remove cell debris and stored at -80°C until analysis. To analyze the growth factors secreted by the cells, the Human Growth Factor Array C1 (RayBiotech, Norcross, GA, USA), capable of detecting 41 types of proteins, was performed according to the manufacturer's instructions. Signals on the membrane were visualized using a LAS-4000 device (GE Healthcare), and the intensity of each spot was calculated using ImageJ with the Protein Array Analyzer macro applied. For inter-group comparison, the intensity of each spot was normalized to the positive control signal and subsequently analyzed semi-quantitatively using the RayBiotech analysis tool software provided by the supplier.
[0189] 8-2: Results of Growth Factor Secretion Capacity Analysis
[0190] To evaluate the secretory capacity of cells thawed after cryopreservation in each cryopreservation composition, human growth factor array analysis was performed on the culture supernatant on the first day after thawing (Fig. 8).
[0191] Looking at Figure 8, among the total of 41 growth factor proteins analyzed, the CBM group showed a significant increase of more than 10% in 10 growth factors compared to the CP group. Among these, granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), amphiregulin (AR), and basic fibroblast growth factor (bFGF) increased by 6.25-fold, 1.23-fold, 1.22-fold, and 1.20-fold, respectively, showing a high increase of more than 20%. On the other hand, the secretion of hepatocyte growth factor (HGF) was found to decrease by 24.7% in the CBM group compared to the CP group.
[0192] Meanwhile, when 0.05 IU / mL of heparin (HEP) was added to the above CBM composition, the secretion of 9 out of a total of 41 growth factors increased significantly by more than 10% compared to the CBM group. In particular, heparin-binding epidermal growth factor-like growth factor (HB-EGF), insulin-like growth factor-binding protein-2 (IGFBP-2), glial cell line-derived neurotrophic factor (GDNF), and bFGF increased by 1.33, 1.27, 1.25, and 1.22 times, respectively, showing a high rate of increase. On the other hand, the secretion of GM-CSF was found to decrease by 47.6% in the HEP-added group compared to the CBM group.
[0193] From the above results, it can be seen that the cryopreservation composition containing heparin, an anticoagulant of the present invention, can regulate the growth factor secretion ability of thawed cells after cryopreservation and increase the secretion of at least some useful growth factors, thereby contributing to the maintenance or enhancement of the function of thawed cells.
[0194] Furthermore, the cryopreservation composition containing heparin according to the present invention can also influence the growth factor secretion profile of cells after thawing. Specifically, in the heparin-added group, the secretion of certain growth factors significantly increased compared to the control group, suggesting that the composition of the present invention can improve functional quality by regulating the secretory capacity of thawed cells, rather than merely increasing cell viability. This effect of regulating secretory capacity can be usefully considered depending on the purpose of cell utilization after thawing.
[0195]
[0196] conclusion
[0197] In summary, it was confirmed that the anticoagulant-added cell cryopreservation composition of the present invention is effective in significantly maintaining or restoring cell functions that are prone to deterioration during the freezing and thawing process. In particular, anticoagulant-class additives such as dalteparin, enoxaparin, and heparin were identified as effective candidates during the screening of candidate additives. Among these, dalteparin, enoxaparin, and heparin at appropriate concentrations showed a tendency to improve at least one of the functions of cell viability, metabolic capacity, proliferation capacity, or adhesion capacity compared to the basic cryopreservation agent alone. Among them, heparin showed a prominent effect in improving proliferation capacity, such as reducing cell doubling time and increasing the expression of proliferation-related markers, and also demonstrated the best cell adhesion capacity. Furthermore, dalteparin and enoxaparin also showed significant improvement effects in some functional indicators, suggesting that the anticoagulant addition strategy according to the present invention can substantially contribute to the recovery of cell functions thawed after cryopreservation.
[0198] Furthermore, although colony-forming ability generally decreased after freezing and thawing, the expression of stem cell markers Oct4, Sox2, and Nanog significantly increased in the heparin-added group, and the expression of CD34, CD45, CD73, and CD90 markers did not show significant differences depending on the type of cryopreservation agent, confirming that the basic surface marker characteristics of the cells were maintained. In addition, since the growth factor secretion profile was regulated in the heparin-added group and the secretion of some useful growth factors increased, the composition of the present invention can serve as an advantageous means to enhance the functional quality and usability of thawed cells, going beyond mere improvement of viability.
[0199] Accordingly, the additive composition for cell cryopreservation agents of the present invention can be usefully applied as a serum-independent or low-risk cryopreservation platform in various cell-based applications requiring cell therapy, stem cell storage, and immediate use after thawing.
[0200]
[0201] Although the present invention has been described as a preferred embodiment mentioned above, various modifications and variations are possible without departing from the essence and scope of the invention. Furthermore, the appended claims include such modifications and variations that fall within the essence of the invention.
Claims
1. An additive composition for a cell cryopreservation agent comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient.
2. In Paragraph 1, A composition characterized in that the above-mentioned cells are stem cells.
3. In Paragraph 2, A composition characterized in that the above-mentioned stem cells are embryonic stem cells, mesenchymal stem cells, or induced pluripotent stem cells.
4. A composition for cell cryopreservation comprising: an additive composition for a cell cryopreservation agent comprising one anticoagulant selected from heparin, dalteparin, and enoxaparin as an active ingredient; and a cell cryopreservation agent.
5. In Paragraph 4, The above composition for cell cryopreservation is characterized by not containing animal or human-derived serum.
6. In paragraph 4, in the above composition The above dalteparin is at a concentration of 0.25 - 500 IU / mL, The above enoxaparin is at a concentration of 0.001 - 4 mg / mL, The above heparin is at a concentration of 0.05 - 200 IU / mL A composition characterized by including 7. In claim 6, in the above composition The above dalteparin is at a concentration of 200-300 IU / mL, The above enoxaparin is at a concentration of 0.005 - 0.2 mg / mL, The above heparin is at a concentration of 0.1 - 1.5 IU / mL A composition characterized by including 8. In Paragraph 4, The above cells are 1×10 per 40 µl of the cell cryopreservation composition 4 Up to 1×10 8 A composition characterized by being added at a concentration of [number].
9. A step of adding cells to a cell cryopreservation composition selected from any one of claims 4 to 8; and A cell cryopreservation method comprising the step of cryopreserving a composition to which the above cells have been added.
10. A step of adding cells to a cell cryopreservation composition selected from any one of claims 4 to 8; A step of cryopreserving the composition to which the above cells have been added; and A method for enhancing the function of thawed cells after cryopreservation, comprising the step of thawing the cryopreserved cells.
